Huperzine A (SPN-817)
Small molecule
Also known as BIS-001
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Dravet Syndrome
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06798896 NCT06798896 · Focal Onset Seizures Registry: NCT06798896 | 2 | Percent change (PCH) from baseline in focal onset seizure frequency per 28 days over the Maintenance Period (Baseline and Maintenance Period (Maintenance Week 1-14)) 2027-08 | In progress: results expected 1 Aug 2027 | not yet graded | link ↗ |
View 1 more trial
NCT03156439 NCT03156439 · Epilepsy, Complex Partial Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Registry: NCT03156439 | 1 | Maximum serum concentration; Cmax (16 Weeks); Area under the curve; AUC (16 Weeks); Time of maximum serum concentration; Tmax (16 Weeks); Half-life; t1/2 (16 Weeks); Terminal elimination (16 Weeks); Clearance (16 Weeks); Volume of distribution (16 Weeks); Mean residence time (16 Weeks) 2017-09-30 | Participants were given the experimental treatment twice a day, with the dose increased every two to three days until a maximum daily dose of 2.5 mg was reached. Participants tolerated the treatment well, with mild to moderate, transient and non-dose-limiting adverse events. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other Acetylcholinesterase drugs
Donepezil (Aricept), GB-5001. Compare all 3 Acetylcholinesterase drugs
2 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for Dravet Syndrome: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Huperzine A (SPN-817): this drug | Stage not on record | Small molecule | Acetylcholinesterase | not yet graded | No reviewed efficacy summary in this indication | |
| Cannabidiol (Epidiolex) | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | Reliable signal | NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2) | |
| Donepezil (Aricept) | Approved(overall) | Small molecule | Acetylcholinesterase | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Fenfluramine (Fintepla) | Approved | Small molecule | Serotonin 5-HT2 receptors | Reliable signal | NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966) NCT02926898: Change in monthly convulsive seizure frequency over titration plus maintenance, fenfluramine 0.4 mg/kg/day (n=43) vs placebo (n=44), in Dravet syndrome on stiripentol-inclusive regimens: 54.0% greater reduction with fenfluramine (95% CI 35.6% to 67.2%); ANCOVA p<0.001 (CT.gov posted analysis). | |
| Stiripentol | Approved | Small molecule | GABA-A receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Clemizole (EPX-100) | Phase 3 | Small molecule | Histamine H1 receptor, Serotonin receptors (5-HT) | not yet graded | No reviewed efficacy summary in this indication | |
| Zorevunersen | Phase 3 | RNA / oligonucleotide | SCN1A mRNA | Weak signal | No reviewed efficacy summary in this indication | |
| Cannabidiol (Kanbis) | Phase 2(overall) | Small molecule | cannabinoid | not yet graded | No reviewed efficacy summary in this indication | |
| GB-5001 | Phase 1(overall) | Small molecule | Acetylcholinesterase | Weak signal(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Huperzine A (SPN-817) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.